The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 43 | Challenges in defining oligometastatic disease and considerations for aggressive surgical treatments
Mitsuru Sasako, MD, PhD, Yodogawa Christian Hospital, Osaka, Japan, discusses the challenges of defining and categorizing oligometastatic disease, emphasizing the difficulty in randomizing patients due to their individual differences. He highlights that in clinical studies, limiting candidates is necessary, but for exceptional responders, aggressive treatment options, such as surgical resection, may still be considered. This interview took place at the ESSO 43 congress in Antwerp, Belgium.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
